CN108137584A - 作为irak抑制剂的6-[5-氨基-6-(2-乙氧基乙氧基)-咪唑并[4,5-b]吡啶-3-基]-烟腈衍生物及其用途 - Google Patents

作为irak抑制剂的6-[5-氨基-6-(2-乙氧基乙氧基)-咪唑并[4,5-b]吡啶-3-基]-烟腈衍生物及其用途 Download PDF

Info

Publication number
CN108137584A
CN108137584A CN201680060910.6A CN201680060910A CN108137584A CN 108137584 A CN108137584 A CN 108137584A CN 201680060910 A CN201680060910 A CN 201680060910A CN 108137584 A CN108137584 A CN 108137584A
Authority
CN
China
Prior art keywords
compound
alkyl
pharmaceutically acceptable
compounds
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680060910.6A
Other languages
English (en)
Chinese (zh)
Inventor
R·C·X·布莱斯
R·J·J·热内
A·M·容古
J·G·P-O·多扬
F·G·拉贝古雷
J-M·勒弗朗索瓦
O·马莫利蒂
B·A·施密特
S·E·范德普拉斯
C·J·M·梅内特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of CN108137584A publication Critical patent/CN108137584A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680060910.6A 2015-10-19 2016-10-14 作为irak抑制剂的6-[5-氨基-6-(2-乙氧基乙氧基)-咪唑并[4,5-b]吡啶-3-基]-烟腈衍生物及其用途 Pending CN108137584A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1518456.7A GB201518456D0 (en) 2015-10-19 2015-10-19 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
GB1518456.7 2015-10-19
PCT/EP2016/074662 WO2017067848A1 (en) 2015-10-19 2016-10-14 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors

Publications (1)

Publication Number Publication Date
CN108137584A true CN108137584A (zh) 2018-06-08

Family

ID=55131239

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680060910.6A Pending CN108137584A (zh) 2015-10-19 2016-10-14 作为irak抑制剂的6-[5-氨基-6-(2-乙氧基乙氧基)-咪唑并[4,5-b]吡啶-3-基]-烟腈衍生物及其用途

Country Status (18)

Country Link
US (1) US10508111B2 (enExample)
EP (1) EP3365341B1 (enExample)
JP (1) JP2018530617A (enExample)
KR (1) KR20180064528A (enExample)
CN (1) CN108137584A (enExample)
AR (1) AR106384A1 (enExample)
AU (1) AU2016343225A1 (enExample)
BR (1) BR112018007392A2 (enExample)
CA (1) CA3002255A1 (enExample)
CO (1) CO2018004765A2 (enExample)
GB (1) GB201518456D0 (enExample)
IL (1) IL258707A (enExample)
MX (1) MX2018004517A (enExample)
PH (1) PH12018500827A1 (enExample)
RU (1) RU2018117499A (enExample)
SG (1) SG11201803095UA (enExample)
TW (1) TW201718582A (enExample)
WO (1) WO2017067848A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113646305A (zh) * 2019-03-29 2021-11-12 加拉帕戈斯股份有限公司 用于治疗炎性障碍的新化合物及其药物组合物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
GB201702603D0 (en) * 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1906190A (zh) * 2004-01-12 2007-01-31 西托匹亚研究有限公司 选择性激酶抑制剂
WO2015048281A1 (en) * 2013-09-27 2015-04-02 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN106061967A (zh) * 2014-01-03 2016-10-26 百时美施贵宝公司 经杂芳基取代的烟酰胺化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28506A1 (es) * 2003-09-12 2005-04-29 Basf Ag 6-halógeno-(1,2,4)triazolo(1,5-a)pirimidinas para combatir plagas animales.
BR112013020329A2 (pt) * 2011-02-09 2016-08-02 Hoffmann La Roche compostos heterocíclicos como inibidores da pi3-quinase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1906190A (zh) * 2004-01-12 2007-01-31 西托匹亚研究有限公司 选择性激酶抑制剂
WO2015048281A1 (en) * 2013-09-27 2015-04-02 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN106061967A (zh) * 2014-01-03 2016-10-26 百时美施贵宝公司 经杂芳基取代的烟酰胺化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113646305A (zh) * 2019-03-29 2021-11-12 加拉帕戈斯股份有限公司 用于治疗炎性障碍的新化合物及其药物组合物

Also Published As

Publication number Publication date
CO2018004765A2 (es) 2018-07-19
EP3365341A1 (en) 2018-08-29
GB201518456D0 (en) 2015-12-02
TW201718582A (zh) 2017-06-01
RU2018117499A (ru) 2019-11-21
AR106384A1 (es) 2018-01-10
IL258707A (en) 2018-06-28
US20180305351A1 (en) 2018-10-25
AU2016343225A1 (en) 2018-05-10
CA3002255A1 (en) 2017-04-27
JP2018530617A (ja) 2018-10-18
WO2017067848A1 (en) 2017-04-27
EP3365341B1 (en) 2020-05-13
KR20180064528A (ko) 2018-06-14
US10508111B2 (en) 2019-12-17
PH12018500827A1 (en) 2018-10-29
BR112018007392A2 (pt) 2018-10-16
MX2018004517A (es) 2018-06-27
SG11201803095UA (en) 2018-05-30
RU2018117499A3 (enExample) 2020-01-24

Similar Documents

Publication Publication Date Title
KR102720958B1 (ko) 질병의 치료를 위한 신규 화합물 및 그의 약학 조성물
KR102758615B1 (ko) 질병의 치료를 위한 신규 화합물 및 그의 약학 조성물
EP3947378B1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CN108137584A (zh) 作为irak抑制剂的6-[5-氨基-6-(2-乙氧基乙氧基)-咪唑并[4,5-b]吡啶-3-基]-烟腈衍生物及其用途
KR20210143905A (ko) 염증성 질환의 치료를 위한 신규 화합물 및 그의 약학 조성물
CN110300586A (zh) 包含irak和jak抑制剂的抗炎组合物
CA3134735A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180608